A detailed history of Northern Trust Corp transactions in Design Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 336,774 shares of DSGN stock, worth $2.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
336,774
Previous 337,345 0.17%
Holding current value
$2.1 Million
Previous $1.13 Million 60.27%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$3.19 - $5.88 $1,821 - $3,357
-571 Reduced 0.17%
336,774 $1.81 Million
Q2 2024

Aug 14, 2024

SELL
$3.23 - $4.77 $64,402 - $95,109
-19,939 Reduced 5.58%
337,345 $1.13 Million
Q1 2024

May 14, 2024

SELL
$2.27 - $4.03 $35,509 - $63,041
-15,643 Reduced 4.19%
357,284 $1.44 Million
Q4 2023

Feb 13, 2024

BUY
$1.99 - $2.76 $98,839 - $137,083
49,668 Added 15.36%
372,927 $988,000
Q3 2023

Nov 13, 2023

SELL
$2.05 - $8.14 $3,031 - $12,039
-1,479 Reduced 0.46%
323,259 $762,000
Q2 2023

Aug 11, 2023

BUY
$4.99 - $7.64 $244,360 - $374,130
48,970 Added 17.76%
324,738 $2.05 Million
Q1 2023

May 15, 2023

SELL
$5.5 - $9.77 $18,491 - $32,846
-3,362 Reduced 1.2%
275,768 $1.59 Million
Q4 2022

Feb 13, 2023

SELL
$7.86 - $17.2 $35,880 - $78,518
-4,565 Reduced 1.61%
279,130 $2.86 Million
Q3 2022

Nov 14, 2022

BUY
$14.09 - $25.57 $361,732 - $656,458
25,673 Added 9.95%
283,695 $4.74 Million
Q2 2022

Aug 12, 2022

BUY
$9.91 - $17.33 $465,651 - $814,302
46,988 Added 22.27%
258,022 $3.61 Million
Q1 2022

May 13, 2022

SELL
$11.17 - $20.89 $10,957 - $20,493
-981 Reduced 0.46%
211,034 $3.41 Million
Q4 2021

Feb 08, 2022

BUY
$13.64 - $21.41 $1.22 Million - $1.91 Million
89,183 Added 72.61%
212,015 $4.54 Million
Q3 2021

Nov 15, 2021

SELL
$13.99 - $20.03 $177,603 - $254,280
-12,695 Reduced 9.37%
122,832 $1.8 Million
Q2 2021

Aug 13, 2021

BUY
$19.02 - $29.78 $2.58 Million - $4.04 Million
135,527 New
135,527 $2.7 Million

Others Institutions Holding DSGN

About Design Therapeutics, Inc.


  • Ticker DSGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,807,900
  • Market Cap $349M
  • Description
  • Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ syste...
More about DSGN
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.